Traduction de «venous thromboembolism on risk » (Néerlandais → Français) :

(Jick 2006) Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or
(Jick 2006) Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing

(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral contraceptives
(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral

(Lidegaard 2009) Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national
(Lidegaard 2009) Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing

Risk of venous thromboembolism in users of oral contraceptives containing
Risk of venous thromboembolism in users of oral contraceptives

(Vasilakis-Scaramozza 2001) Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
(Vasilakis-Scaramozza 2001) Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or

Boutitie F, Pinede L, Schulman S et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participant’s data from seven trials.
Oudega R, Van Weert H, Stoffers H et al. NHG-Standaard: Diepe veneuze trombose.

G. Lowe en P. Sandercock: Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance?
G. Lowe et P. Sandercock: Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance?

H. Büller en M. Prins: Secondary prophylaxis with warfarin for venous thromboembolism (editorial).
H. Büller et M. Prins: Secondary prophylaxis with warfarin for venous thromboembolism (editorial).

De risk/benefit balans moet in overweging worden genomen bij patiënten die een risico lopen op trombo-embolische voorvallen (TEE, thromboembolic events) van welke oorsprong dan ook.
Le rapport bénéfice/risque doit être évalué chez les patients à risque d'évènements thrombo-emboliques (ETE) quelle qu'en soit l'étiologie.